The University of Chicago Header Logo

Connection

Joel R. Pekow to Inflammatory Bowel Diseases

Back to Details
This is a "connection" page, showing publications Joel R. Pekow has written about Inflammatory Bowel Diseases.
Joel R. Pekow
Connection Strength
4.899
Inflammatory Bowel Diseases
  1. Fatigue in Inflammatory Bowel Disease: A Common Complaint With Few Answers. Gastroenterology. 2022 11; 163(5):1164-1165.
    View in: PubMed
    Score: 0.549
  2. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Reply Letter to Elia et al. Inflamm Bowel Dis. 2020 08 20; 26(9):e94.
    View in: PubMed
    Score: 0.477
  3. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.467
  4. IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. J Crohns Colitis. 2019 Jul 25; 13(7):884-893.
    View in: PubMed
    Score: 0.443
  5. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
    View in: PubMed
    Score: 0.388
  6. MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis. 2012 Jan; 18(1):187-93.
    View in: PubMed
    Score: 0.248
  7. Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023 Jun; 29(6):1520-1529.
    View in: PubMed
    Score: 0.145
  8. Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
    View in: PubMed
    Score: 0.138
  9. The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD). Inflamm Bowel Dis. 2022 02 01; 28(2):192-199.
    View in: PubMed
    Score: 0.132
  10. Whole-genome sequencing of African Americans implicates differential genetic architecture in inflammatory bowel disease. Am J Hum Genet. 2021 03 04; 108(3):431-445.
    View in: PubMed
    Score: 0.123
  11. Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
    View in: PubMed
    Score: 0.123
  12. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
    View in: PubMed
    Score: 0.120
  13. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3.
    View in: PubMed
    Score: 0.120
  14. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.
    View in: PubMed
    Score: 0.111
  15. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.110
  16. Linear and circular CDKN2B-AS1 expression is associated with Inflammatory Bowel Disease and participates in intestinal barrier formation. Life Sci. 2019 Aug 15; 231:116571.
    View in: PubMed
    Score: 0.110
  17. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019 05 16; 25(Suppl 2):S40-S47.
    View in: PubMed
    Score: 0.109
  18. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
    View in: PubMed
    Score: 0.109
  19. Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 11 29; 24(12):2634-2640.
    View in: PubMed
    Score: 0.106
  20. Identification of novel mRNAs and lncRNAs associated with mouse experimental colitis and human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2018 11 01; 315(5):G722-G733.
    View in: PubMed
    Score: 0.103
  21. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
    View in: PubMed
    Score: 0.100
  22. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
    View in: PubMed
    Score: 0.100
  23. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
    View in: PubMed
    Score: 0.096
  24. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther. 2017 07; 46(2):162-168.
    View in: PubMed
    Score: 0.095
  25. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
    View in: PubMed
    Score: 0.093
  26. Activation of the Renin-Angiotensin System Promotes Colitis Development. Sci Rep. 2016 06 08; 6:27552.
    View in: PubMed
    Score: 0.089
  27. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013 Sep; 123(9):3983-96.
    View in: PubMed
    Score: 0.073
  28. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2016 Apr; 43(7):790-801.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.